Esperion Therapeutics, Inc. – LSE:0IIM.L

Add to watchlist

$5.065

+2.74

+118.32%

Market closed

Open in about 15 hours

-6.83%

month

-6.83%

quarter

-16.55%

year

Market Cap	436.43M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.97

Revenue	229.74M
EBITDA	-34.68M
Income	-86.50M
Revenue Q/Q	466.13%
Revenue Y/Y	183.74%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-15.1%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Esperion Therapeutics, Inc. (LSE:0IIM.L): Profit margin
Jun 2023	25.78M	-49.93M	-193.65%
Sep 2023	33.96M	-41.25M	-121.43%
Dec 2023	32.25M	-56.34M	-174.71%
Mar 2024	137.73M	61.02M	44.3%

Esperion Therapeutics Financials Estimate

Q Y

Esperion Therapeutics, Inc. (LSE:0IIM.L): Analyst Estimates
Mar 2024	137.73M	61.02M	44.3%
Sep 2025	91.6M	5.62M	6.14%
Oct 2025	103.6M	15.17M	14.64%
Dec 2025	200M	111.88M	55.94%

Analysts Price target
Financials & Ratios estimates

Esperion Therapeutics, Inc. (LSE:0IIM.L): Debt to assets
Jun 2023	234626000	606.60M	258.54%
Sep 2023	221305000	631.30M	285.27%
Dec 2023	205796000	660.79M	321.09%
Mar 2024	373060000	667.35M	178.89%

Esperion Therapeutics, Inc. (LSE:0IIM.L): Cash Flow
Jun 2023	-24.75M	17.5M	809K
Sep 2023	-19.32M	0	-4.31M
Dec 2023	-37.05M	0	4.47M
Mar 2024	53.82M	-73K	90.60M

Esperion Therapeutics alternative data

Esperion Therapeutics
Employees

Esperion Therapeutics, Inc. (LSE:0IIM.L): Employee count
Aug 2023	199
Sep 2023	199
Oct 2023	199
Nov 2023	199
Dec 2023	199
Jan 2024	199
Feb 2024	199
Mar 2024	240
Apr 2024	240
May 2024	240
Jun 2024	240
Jul 2024	240

Status	Patent	Filling date	Issue date
Application	Application METHODS OF MAKING BEMPEDOIC ACID AND COMPOSITIONS OF THE SAME Filling date: 12 May 2022 Issue date: 8 Sep 2022	12 May 2022	8 Sep 2022
Application	Application PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULATED BEMPEDOIC ACID Filling date: 14 Apr 2022 Issue date: 11 Aug 2022	14 Apr 2022	11 Aug 2022
Grant	Grant Utility: Methods of making bempedoic acid and compositions of the same Filling date: 15 Jan 2021 Issue date: 9 Aug 2022	15 Jan 2021	9 Aug 2022
Application	Application FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE Filling date: 2 Sep 2021 Issue date: 14 Apr 2022	2 Sep 2021	14 Apr 2022
Application	Application HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES Filling date: 1 Feb 2021 Issue date: 23 Dec 2021	1 Feb 2021	23 Dec 2021
Application	Application FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE Filling date: 29 Dec 2020 Issue date: 25 Nov 2021	29 Dec 2020	25 Nov 2021
Application	Application TRIPLET COMBINATION FORMULATIONS AND METHODS FOR TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE Filling date: 8 Feb 2018 Issue date: 25 Nov 2021	8 Feb 2018	25 Nov 2021
Application	Application METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES Filling date: 26 Aug 2019 Issue date: 21 Oct 2021	26 Aug 2019	21 Oct 2021
Application	Application COMBINATION DRUG FORMULATIONS FOR TREATING PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS Filling date: 26 Aug 2019 Issue date: 21 Oct 2021	26 Aug 2019	21 Oct 2021
Grant	Grant Utility: Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease Filling date: 16 Mar 2016 Issue date: 14 Sep 2021	16 Mar 2016	14 Sep 2021

Esperion Therapeutics
Executives

Insider	Age	Compensation
Mr. Timothy M. Mayleben M.B.A. (1961) Pres, Chief Executive Officer & Director	64	$1,080,000
Mr. Mark A. Glickman (1966) Chief Commercial Officer	59	$624,390
Mr. Richard B. Bartram (1982) Chief Financial Officer & Corporation Sec.	43	$485,500
Dr. Kenneth J. Fiorelli Chief Technical Operations Officer
Mr. Keith F. Lenden Vice President of Corporation Devel. & Strategy
Roberta Peterson Senior Director of National Accounts
Renee Marotta Head of Marketing
Ms. April Seiler Senior Director of Project Management
Mr. Benjamin Church Head of Corporation Communications & Investor Relations
Ms. Ashley Hall Chief Devel. Officer

Frequently Asked Questions (FAQ)

What's the price of Esperion Therapeutics stock today?

One share of Esperion Therapeutics stock can currently be purchased for approximately $5.07.
When is Esperion Therapeutics's next earnings date?

Unfortunately, Esperion Therapeutics's (0IIM.L) next earnings date is currently unknown.
Does Esperion Therapeutics pay dividends?

No, Esperion Therapeutics does not pay dividends.
How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of 436.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 54.14% to 116.33M US dollars.
What is Esperion Therapeutics's stock symbol?

Esperion Therapeutics, Inc. is traded on the LSE under the ticker symbol "0IIM.L".
What is Esperion Therapeutics's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Esperion Therapeutics?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Esperion Therapeutics's key executives?
Esperion Therapeutics's management team includes the following people:
- Mr. Timothy M. Mayleben M.B.A. Pres, Chief Executive Officer & Director(age: 64, pay: $1,080,000)
- Mr. Mark A. Glickman Chief Commercial Officer(age: 59, pay: $624,390)
- Mr. Richard B. Bartram Chief Financial Officer & Corporation Sec.(age: 43, pay: $485,500)
- Dr. Kenneth J. Fiorelli Chief Technical Operations Officer
- Mr. Keith F. Lenden Vice President of Corporation Devel. & Strategy
- Roberta Peterson Senior Director of National Accounts
- Renee Marotta Head of Marketing
- Ms. April Seiler Senior Director of Project Management
- Mr. Benjamin Church Head of Corporation Communications & Investor Relations
- Ms. Ashley Hall Chief Devel. Officer
How many employees does Esperion Therapeutics have?

As Jul 2024, Esperion Therapeutics employs 240 workers.
When Esperion Therapeutics went public?

Esperion Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
What is Esperion Therapeutics's official website?

The official website for Esperion Therapeutics is esperion.com.
Where are Esperion Therapeutics's headquarters?

Esperion Therapeutics is headquartered at 3891 Ranchero Drive, Ann Arbor, MI.
How can i contact Esperion Therapeutics?

Esperion Therapeutics's mailing address is 3891 Ranchero Drive, Ann Arbor, MI and company can be reached via phone at +7 348873903.

Esperion Therapeutics, Inc.

esperion.com

Exchange:

LSE

Full time employees:

240

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

+7 348873903

3891 Ranchero Drive
Ann Arbor, MI 48108

:
ISIN: US29664W1053
: